ClinicalTrials.Veeva

Menu

SMART Protocol vs Antagonist Protocol in IVF

O

Ovo Clinic

Status

Completed

Conditions

Diminished Ovarian Reserve

Study type

Observational

Funder types

Industry

Identifiers

NCT05677828
CCER 21-22 - 21

Details and patient eligibility

About

This retrospective study aims to assess the effect of adding letrozole in patients who have previously undergone an IVF cycle with either an antagonist or short protocol, with patients who have undergone a second cycle of IVF with an antagonist or short protocol without the addition of letrozole.

Full description

A limited number of studies suggest that the addition of letrozole to gonadotropins for IVF is associated with an increase in oocyte count, blastocyst count and implantation rate. These differences are presumed to be caused by an increase in intra-ovarian androgens associated with the addition of letrozole.

In patients with reduced ovarian reserve or reduced oocyte quality in the previous cycle, supplementation with of letrozole has the potential to increase oocyte count or oocyte quality, thereby resulting in more transferable blastocysts. The antagonist stimulation protocol with the addition of letrozole is commonly referred to as the SMART protocol (Stimulation with Minimal Adverse effects, Retrieval and Transfer

Enrollment

426 patients

Sex

Female

Ages

20 to 42 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for the SMART IVF protocol:

  • Women between the ages of 20 and 42 inclusively
  • Women proceeding with a SMART IVF protocol following an antagonist IVF protocol between 2010 and 2020 (study group) or women proceeding with an antagonist protocol following an antagonist IVF protocol between 2010 and 2020 (control group)
  • Delay of 1 year between both IVF cycle

Exclusion Criteria:

  • Women undergoing fertility preservation
  • Oocyte donation IVF cycles
  • Diagnosed severe male factor requiring surgical sperm extraction (micro-tese or TESA)

Trial design

426 participants in 2 patient groups

Antagonist - SMART
Description:
Women who have had a SMART IVF stimulation cycle with Letrozole after a failed antagonist IVF stimulation cycle between 2010 and 2020.
Antagonist - Antagonist
Description:
Women who have had an antagonist stimulation IVF cycle after a previously failed antagonist IVF stimulation cycle between 2010 and 2020.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems